XML 22 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1Close
Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Net sales $ 3,856 $ 3,389
Cost of products sold 1,209 1,040
Gross profit 2,648 2,349 Close
Operating expenses:     Close
Selling, general and administrative expenses 1,364 1,215 Close
Research and development expenses 366 337 Close
Royalty expense 10 11 Close
Amortization expense 214 203 Close
Contingent consideration net expense (benefit) 17 12 Close
Restructuring net charges (credits) 3 20 Close
Operating expenses 1,973 1,797 CloseClose
Operating income (loss) 675 552 Close
Other income (expense):     Close
Interest expense (69) (65) CloseCloseCloseCloseCloseCloseCloseCloseClose
Other, net 2 (43) CloseCloseCloseCloseCloseCloseCloseCloseCloseClose
Total Other Income Expenses 537.0 336.0 0.0 0.0 0.0 Close
Income (loss) before income taxes 608 444 CloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseCloseClose
Income tax expense (benefit) 115 131 Close
Net income (loss) 493 314 Close
Preferred stock dividends 0 (14)
Net income (loss) attributable to noncontrolling interests (1) 0
Net income (loss) attributable to Boston Scientific common stockholders $ 495 $ 300
Net income (loss) per common share — basic $ 0.34 $ 0.21
Net income (loss) per common share — diluted $ 0.33 $ 0.21
Weighted-average shares outstanding    
Basic 1,468.4 1,435.8
Diluted 1,481.7 1,446.0